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tion between the tumor and its surrounding microenvironment and contributions from social genomics, which has begun to map the biological pathways through which social and psychological processes can be involved in gene regulation.
Cole helps us understand how biological pathways involved in stress response that is relevant for the field of psycho-oncology. He thereby focuses on the intriguing yet understudied interplay between psychosocial interventions and their possible molecular effects on disease progression. For example, he comments, "… disease-predictive molecular biomarkers provide new opportunities for gauging the biological impacts of psycho-oncologic interventions, as well as selecting optimal intervention protocols on a patient-specific basis." (p. 2308). 1 Cole finalizes his editorial with sketching a future where psychooncologists add to their tool kit of psychological assessments molecular measures to assess the somatic impact of psychological well-being.
We wholeheartedly endorse Cole's plea for such expansion of psychooncology's toolkit and research agenda.
We believe the field of psycho-oncology will further benefit from examining the direct relationships between genetic and molecular variables and biological pathways underlying patients' subjective experiences, such as quality of life (QOL). This idea is almost 15 years old. 2 It was fueled by the emerging evidence of a genetic basis of QOL based on twin research that indicated heritability estimates for stress 3 and QOL-related domains such as mood and self-reported health 4 that were comparable or even higher than that of most diseases (20%-40%). A stimulating first finding was the direct links between polymorphisms and cancer patients' QOL. 2 To enable the identification of biological pathways and genetic and molecular variables underlying patients' QOL, we established the Research into the biological pathways, genetic, and molecular variables and epigenetic mechanisms involved in subjective health and symptom experiences is thus well underway. 10 The resulting scientific insights are a prerequisite for possible important clinical implications and the potential to improve the quality of health care delivery. Knowledge of how biological predispositions propel people toward negative or away from positive health experiences will allow us to identify patients who are likely to experience symptoms and QOL deficits from cancer and its treatments. As a consequence, oncologists may be able to intervene prophylactically, monitor patients' symptoms, side effects, and well-being, improve treatment decision-making, and improve outcomes encompassing survival, toxicity, and QOL. To cite Sloan and Zhao, "Doctors will eventually use genetic patterns for several tasks: to tell whether a cancer will spread, to predict how various therapies such as specific drugs or radiation
